ArticleInternational journal of molecular medicine2019
MicroRNA-204 inhibits the proliferation, migration and invasion of human lung cancer cells by targeting PCNA-1 and inhibits tumor growth in vivo.
Article in International journal of molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Effects of Telerehabilitation Based on Motion Recognition Technology on Exercise Endurance of Patients With Non-Small Cell Lung Cancer After Surgery: Single-Center, Prospective, Open-Label, Randomized Controlled Trial.JMIR mHealth and uHealth · 2026Trial
- Tumor Suppressor miRNA-based Signatures in Triple Negative Breast Cancer: A Study Based on Big Data Analysis of Gene Expression Omnibus (GEO) Datasets and Its Validation.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Role of Sam68 in different types of cancer (Review).International journal of molecular medicine · 2025Review
- Tumoral Malignancy Decreases Coupled with Higher ROS and Lipid Peroxidation in HCT116 Colon Cancer Cells upon Loss of PRDX6.Antioxidants (Basel, Switzerland) · 2024Article
- Anti-proliferative and apoptotic effect of cannabinoids on human pancreatic ductal adenocarcinoma xenograft in BALB/c nude mice model.Scientific reports · 2024Article
- Article
- MicroRNA-889-3p restrains the proliferation and epithelial-mesenchymal transformation of lung cancer cells via down-regulation of Homeodomain-interacting protein kinase 1.Bioengineered · 2021Article
- MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells.Oncology letters · 2021Article
- lncRNA TPTEP1 inhibits stemness and radioresistance of glioma through miR‑106a‑5p‑mediated P38 MAPK signaling.Molecular medicine reports · 2020Article
- Review
- Knockdown of the long noncoding RNA XIST suppresses glioma progression by upregulating miR-204-5p.Journal of Cancer · 2020Article
- MicroRNA Dysregulation in Cutaneous Squamous Cell Carcinoma.International journal of molecular sciences · 2019Review
Corrections and comments
- Retraction · 2024-12-09Concerns/Issues about Data · Euphemisms for Plagiarism · Investigation by Journal/Publisher · Investigation by Third Party · Plagiarism of Data · · See also: https://pubpeer.com/publications/AC78854ED17EA3AE1DF7F1C4EF30C4
- Retracted
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer accounts for ~20% of the total cancer‑associated mortalities worldwide. Lung cancer is often diagnosed at advanced stages and is therefore difficult to treat. The biomarkers for diagnosis of lung cancer are limited and unreliable. In addition, the lack of availability of efficient chemotherapeutic agents and targets has resulted in limitations in the successful treatment of lung cancer. Previously, microRNAs (miRNA/miR) have been implicated in the onset and development of several types of cancer. The expression of miRNAs is often dysregulated in cancer cells; therefore, they are considered important therapeutic targets and agents. The present study examined the expression of miR‑204 in 4 different lung cancer cell lines and 1 normal cell line. The results revealed that miR‑204 was significantly downregulated (4‑8‑fold) in all the cancer cell lines (P<0.05). Overexpression of miR‑204 in A549 lung cancer cells inhibited the proliferative, migratory and invasive capabilities of the lung cancer cells. Furthermore, miR‑204 overexpression also induced apoptosis in the A549 lung cancer cells. Bioinformatics analysis revealed proliferating cell nuclear antigen 1 (PCNA‑1) to be a potential target of miR‑204. The reverse transcription quantitative polymerase chain reaction analysis revealed that PCNA‑1 was significantly upregulated (up to 5‑fold) in the lung cancer cells (P<0.05), and the overexpression of miR‑204 caused the downregulation of PCNA‑1 in A549 lung cancer cells. Silencing of PCNA‑1 in A549 cells exerted similar effects to that of miR‑204 overexpression on the proliferative, migratory and invasive capabilities of A549 lung cancer cells. Additionally, the suppression of miR‑204 in A549 cells transfected with Si‑PCNA‑1 did not rescue the effects of PCNA‑1 silencing on cell proliferation, migration or invasion. Conversely, the overexpression of PCNA‑1 in A549 cells transfected with miR‑204 mimics promoted the proliferation, migration and invasion of lung cancer cells. Furthermore, overexpression of miR‑204 in xenograft tumors significantly inhibited their growth. Taken together, these results indicated that miR‑204 regulates the proliferative, migratory and invasive capabilities of lung cancer cells by targeting PCNA‑1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.